MX2023009278A - Compuestos ciclicos aromaticos pirimidina. - Google Patents

Compuestos ciclicos aromaticos pirimidina.

Info

Publication number
MX2023009278A
MX2023009278A MX2023009278A MX2023009278A MX2023009278A MX 2023009278 A MX2023009278 A MX 2023009278A MX 2023009278 A MX2023009278 A MX 2023009278A MX 2023009278 A MX2023009278 A MX 2023009278A MX 2023009278 A MX2023009278 A MX 2023009278A
Authority
MX
Mexico
Prior art keywords
aromatic ring
ring compounds
pyrimidine
pyrimidine aromatic
compounds
Prior art date
Application number
MX2023009278A
Other languages
English (en)
Inventor
Wentao Wu
Yang Zhang
Shuhui Chen
Yangyang Xu
Zhixiang Li
Kaijun Geng
Original Assignee
Usynova Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usynova Pharmaceuticals Ltd filed Critical Usynova Pharmaceuticals Ltd
Publication of MX2023009278A publication Critical patent/MX2023009278A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan compuestos cíclicos aromáticos pirimidina. Se proporciona específicamente un compuesto representado por la fórmula (II) o una sal farmacéuticamente aceptable del mismo. (ver Fórmula).
MX2023009278A 2021-02-09 2022-02-09 Compuestos ciclicos aromaticos pirimidina. MX2023009278A (es)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN202110182357 2021-02-09
CN202110251656 2021-03-08
CN202110379326 2021-04-08
CN202110485837 2021-04-30
CN202110825879 2021-07-21
CN202110975205 2021-08-24
CN202111136266 2021-09-27
CN202111283561 2021-11-01
CN202210072243 2022-01-21
CN202210113080 2022-01-29
PCT/CN2022/075732 WO2022171147A1 (zh) 2021-02-09 2022-02-09 嘧啶并芳香环类化合物

Publications (1)

Publication Number Publication Date
MX2023009278A true MX2023009278A (es) 2023-08-17

Family

ID=82837454

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009278A MX2023009278A (es) 2021-02-09 2022-02-09 Compuestos ciclicos aromaticos pirimidina.

Country Status (11)

Country Link
US (1) US20240174692A1 (es)
EP (1) EP4293027A4 (es)
JP (1) JP2024505594A (es)
KR (1) KR20230136636A (es)
CN (1) CN116888128A (es)
AU (1) AU2022219124A1 (es)
BR (1) BR112023015976A2 (es)
CA (1) CA3207800A1 (es)
IL (1) IL305033A (es)
MX (1) MX2023009278A (es)
WO (1) WO2022171147A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115141215B (zh) * 2021-03-30 2023-09-15 上海德琪医药科技有限公司 Kras g12d蛋白抑制剂和其用途
WO2023039240A1 (en) * 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023061294A1 (zh) * 2021-10-13 2023-04-20 再鼎医药(上海)有限公司 含氮杂环类衍生物调节剂、其制备方法及应用
WO2023072188A1 (zh) * 2021-10-29 2023-05-04 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
CN118556063A (zh) * 2022-01-21 2024-08-27 上海湃隆生物科技有限公司 杂环类化合物、药物组合物及其应用
WO2023138662A1 (zh) * 2022-01-21 2023-07-27 南京明德新药研发有限公司 苯并嘧啶类化合物及其应用
WO2023152255A1 (en) * 2022-02-10 2023-08-17 Bayer Aktiengesellschaft Fused pyrimidines as kras inhibitors
WO2024008179A1 (en) * 2022-07-07 2024-01-11 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
CN117263959A (zh) * 2022-10-24 2023-12-22 药雅科技(上海)有限公司 芳香类kras突变蛋白抑制剂的制备及其应用
CN116082115A (zh) * 2023-01-06 2023-05-09 河南省科学院化学研究所有限公司 一种2-溴-4-氯-9,9’-二甲基芴的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190186A1 (ar) * 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
EP3887373A1 (en) * 2018-11-29 2021-10-06 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
WO2020177629A1 (zh) * 2019-03-01 2020-09-10 劲方医药科技(上海)有限公司 螺环取代的嘧啶并环类化合物，其制法与医药上的用途
CN112110918B (zh) * 2019-06-21 2023-08-22 劲方医药科技(上海)有限公司 螺环取代的嘧啶并环类化合物，其制法与医药上的用途
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
JP2023531269A (ja) * 2020-06-30 2023-07-21 インベンティスバイオ カンパニー リミテッド キナゾリン化合物、その製造方法および用途
JP2023540270A (ja) * 2020-08-28 2023-09-22 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物およびその使用
WO2022061251A1 (en) * 2020-09-18 2022-03-24 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
CN114031562A (zh) * 2021-10-31 2022-02-11 南京碳硅人工智能生物医药技术研究院有限公司 一种具有抗肿瘤的吡啶衍生物的工艺优化

Also Published As

Publication number Publication date
CN116888128A (zh) 2023-10-13
IL305033A (en) 2023-10-01
EP4293027A4 (en) 2024-08-14
EP4293027A1 (en) 2023-12-20
US20240174692A1 (en) 2024-05-30
BR112023015976A2 (pt) 2023-12-12
CA3207800A1 (en) 2022-08-18
JP2024505594A (ja) 2024-02-06
AU2022219124A1 (en) 2023-08-31
WO2022171147A1 (zh) 2022-08-18
KR20230136636A (ko) 2023-09-26

Similar Documents

Publication Publication Date Title
MX2023009278A (es) Compuestos ciclicos aromaticos pirimidina.
MX2022011283A (es) Compuestos pirimidoheterocíclicos y aplicación de los mismos.
CR20210032A (es) Compuestos
CR20220354A (es) Inhibidores de egfr
MX2021013531A (es) Inhibidores de cdk.
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2021007017A (es) Inhibidor de la 15-pgdh.
ZA202201503B (en) Urea compound for antagonizing lpa1 receptor
MX2009012125A (es) Compuestos terapeuticos.
CR20240173A (es) Compuestos de cd73
MX2024002503A (es) Nuevo compuesto heterociclico sustituido con aril eter como agonista de glp1r.
MX2022004168A (es) Compuestos aromaticos de arilmetileno a manera de bloqueadores del canal de potasio kv1.3.
ZA202308002B (en) Pyrimidopyran compound
MX2023001418A (es) Forma sólida de compuesto.
ZA202101487B (en) Novel compounds
MX2024008849A (es) Compuestos de benzopirimidina y uso de estos.
CR20240014A (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
EA202091481A1 (ru) Замещенные алкиниленовые соединения в качестве противораковых агентов
MX2021014629A (es) Compuestos tetraciclicos como inhibidores de cdc7.
MX2021009752A (es) Derivado de 7h-pirrolo[2,3-d]pirimidin-4-amina.
MX2009012124A (es) Compuestos terapeuticos estereoisomeros de propofol.
MX2022004144A (es) Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
WO2021087086A8 (en) Condensed pyridazine or pyrimidine as btk inhibitors
MX2021014458A (es) Compuestos triciclicos.
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.